Hearing Changes After Surgery
Launched by GATEWAY BIOTECHNOLOGY, INC. · Mar 24, 2020
Trial Information
Current as of August 02, 2025
Withdrawn
Keywords
ClinConnect Summary
High-speed drills that are capable of producing elevated levels are used during skull based surgeries (Hilmi et al., 2011; Yu et al., 2014). Recently, it has been shown that surgical drilling may have a temporary effect on the amplitude of the otoacoustic emissions of the ear contralateral to the surgical site (Baradaranfar et al., 2015; Shenoy et al., 2015), however the temporary effects of surgical noise or vibration on the hearing of the non-surgical related ear needs to be better quantified. This study aims to to measure the potential effects of surgical drilling noise and/or vibration ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • participants are undergoing a skull-based or mastoid surgery for treatment of an affected ear
- • participants have normal or near-normal hearing thresholds in the un-operated ear
- Exclusion Criteria:
- • participants have hearing loss (PTA \> 40 dB HL) in pure tone audiometry testing before surgery in the un-operated ear
- • participants have medical conditions after the surgery which prevents having hearing tests
- • participants have abnormal tympanometric results
About Gateway Biotechnology, Inc.
Gateway Biotechnology, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions through rigorous research and development. With a focus on biotechnology and pharmaceutical advancements, the company is committed to conducting high-quality clinical trials that prioritize patient safety and scientific integrity. Leveraging a team of experienced professionals and cutting-edge technology, Gateway Biotechnology aims to facilitate the efficient progression of novel treatments from the laboratory to the clinic, ultimately improving patient outcomes and contributing to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Partha Thirumala, MD
Principal Investigator
University of Pittsburgh Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials